Publikationen, an denen er mitarbeitet Miguel Ángel Sanz Alonso (29)

2023

  1. Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia

    Blood Advances, Vol. 7, Núm. 1, pp. 167-173

2021

  1. Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia

    Leukemia, Vol. 35, Núm. 8, pp. 2358-2370

2020

  1. Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project

    Haematologica, Vol. Online ahead of print

2018

  1. Focal adhesion genes refine the intermediate-risk cytogenetic classification of acute myeloid leukemia

    Cancers, Vol. 10, Núm. 11

2017

  1. NEDD 9 an independent good prognostic factor in intermediaterisk acute myeloid leukemia patients

    Oncotarget, Vol. 8, Núm. 44, pp. 76003-76014

2015

  1. CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia

    Haematologica

2012

  1. Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen

    Bone Marrow Transplantation, Vol. 47, Núm. 10, pp. 1287-1293

2011

  1. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens

    Blood, Vol. 117, Núm. 6, pp. 1799-1805

  2. Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy

    Haematologica, Vol. 96, Núm. 10, pp. 1470-1477

2010

  1. Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy

    Haematologica, Vol. 95, Núm. 3, pp. 424-431

  2. Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group

    Blood, Vol. 116, Núm. 25, pp. 5650-5659

2009

  1. Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis

    Haematologica, Vol. 94, Núm. 9, pp. 1242-1249

  2. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all- trans retinoic acid and anthracycline chemotherapy: Characteristics, outcome, and prognostic factors

    Blood, Vol. 113, Núm. 4, pp. 775-783

2008

  1. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin

    Blood, Vol. 111, Núm. 7, pp. 3395-3402

  2. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: Long-term outcome of the LPA 99 multicenter study by the PETHEMA Group

    Blood, Vol. 112, Núm. 8, pp. 3130-3134

2007

  1. Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): Benefit of an early intervention

    Leukemia, Vol. 21, Núm. 3, pp. 446-452

  2. Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia

    British Journal of Haematology, Vol. 136, Núm. 4, pp. 590-596

2005

  1. Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: A multicenter study by the PETHEMA Group

    Journal of Clinical Oncology, Vol. 23, Núm. 30, pp. 7632-7640

2004

  1. Quantitative assessment of PML-RARa and BCR-ABL by two real-time PCR instruments: Multiinstitutional laboratory trial

    Clinical Chemistry, Vol. 50, Núm. 6, pp. 1088-1092

  2. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: A multicenter study by the PETHEMA group

    Blood, Vol. 103, Núm. 4, pp. 1237-1243